Epigenomic targets for the treatment of respiratory disease

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 6, 2009, Pages 625-640

  Bowman, Rayleen V ^a,b   Wright, Casey M ^a,b   Davidson, Morgan R ^a,b   Savarimuthu Francis, Santiyagu M ^a,b   Yang, Ian A ^a   Fong, Kwun M ^a,b  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Dna methylation; Epigenesis; Lung neoplasms

Indexed keywords

ACETYL COENZYME A ACYLTRANSFERASE; ANTISENSE OLIGONUCLEOTIDE; APC; APC PROTEIN; BIOLOGICAL MARKER; CORTICOSTEROID; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEATH ASSOCIATED PROTEIN KINASE; DNA METHYLTRANSFERASE 1; ESTROGEN RECEPTOR; FRAGILE HISTIDINE TRIAD PROTEIN; GLUTATHIONE TRANSFERASE P1; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 20; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; OSTEOGENIN; PIVALOYLOXYMETHYL BUTYRATE; PROTEIN MLH1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNINDEXED DRUG; UVOMORULIN; VORINOSTAT;

AIR POLLUTION; ASTHMA; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE; GENE TARGETING; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; METASTASIS; NONHUMAN; PROTEIN FUNCTION; RECURRENT CANCER; RESPIRATORY TRACT DISEASE; REVIEW; UNSPECIFIED SIDE EFFECT;

CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENOMICS; HISTONES; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; MICRORNAS; RESPIRATORY TRACT DISEASES;

EID: 67649625532     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220902926119     Document Type: Review

References (146)

1. The American Association for Cancer Research Human Epigenome Task Force and The European Union NoE, Scientific Advisory Board. Moving AHEAD with an international human epigenome project. Nature 2008;454(7205):711-715
2. Hotchkiss R. The quantitative separation of purines, pyrimidines and nucleosides by paper chromatography. J Biol Chem 1948;168:315-332
3. Luczak MW, Jagodzinski PP. The role of DNA methylation in cancer development. Folia Histochem Cytobiol 2006;44(3):143-154 (Pubitemid 44131981)
4. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004;22(22):4632-4642 (Pubitemid 41185132)
5. Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem 2005;74:481-514 (Pubitemid 40995515)
6. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986;321(6067):209-213 (Pubitemid 16016411)
7. Momparler RL. Cancer epigenetics. Oncogene 2003;22(42):6479-6483 (Pubitemid 37372327)
8. Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000;24(2):132-138 (Pubitemid 30094712)
9. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001;291(5507):1304-1351 (Pubitemid 32173090)
10. Zilberman D. The human promoter methylome. Nat Genet 2007;39(4):442-443 (Pubitemid 46514760)
11. Knudson Jr AG. Mutation and Cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-823
12. Costello JF, Plass C. Methylation matters. J Med Genet 2001;38(5):285-303 (Pubitemid 32433981)
13. Morse B, Rotherg PG, South VJ, et al. Insertional mutagenesis of the myc locus by a LINE-1 sequence in a human breast carcinoma. Nature 1988;333(6168):87-90 (Pubitemid 18109000)
14. Soares J, Pinto AE, Cunha CV, et al. Global DNA hypomethylation in breast carcinoma: correlation with prognostic factors and tumor progression. Cancer 1999;85(1):112-118 (Pubitemid 29031364)
15. Calvisi DF, Ladu S, Gorden A, et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007;117(9):2713-2722 (Pubitemid 47494371)
16. Cho NY, Kim BH, Choi M, et al. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol 2007;211(3):269-277 (Pubitemid 46172702)
17. Widschwendter M, Jiang G, Woods C, et al. DNA hypomethylation and ovarian cancer biology. Cancer Res 2004;64(13):4472-4480 (Pubitemid 38856918)
18. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 2007;16(1):R50-9 (Pubitemid 47241842)
19. Komatsu N, Kawamata N, Takeuchi S, et al. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Rep 2006;15(1):187-191
20. Desai D, Das A, Cohen L, et al. Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice. Anticancer Res 2003;23(1A):499-503 (Pubitemid 36358560)
21. Loprevite M, Tiseo M, Grossi F, et al. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res 2005;15(1):39-48
22. Mukhopadhyay NK, Weisberg E, Gilchrist D, et al. Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer. Ann Thorac Surg 2006;81(3):1034-1042 • This paper presents in vitro evidence for the effect of an HDAC inhibitor against non-small cell lung cancer cell lines. (Pubitemid 43247683)
23. Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet 2004;5(5):396-400 (Pubitemid 38529411)
24. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64(11):3753-3756 (Pubitemid 38697282)
25. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9(3):189-198 (Pubitemid 43357945)
26. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008;13(1):48-57 (Pubitemid 350309743)
27. Markou A, Tsaroucha EG, Kaklamanis L, et al. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 2008;54(10):1696-1704
28. Hu Z, Chen J, Tian T, et al. Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest 2008;118(7):2600-2608 (Pubitemid 351949787)
29. Weber B, Stresemann C, Brueckner B, Lyko F. Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle 2007;6(9):1001-1005 (Pubitemid 46708569)
30. Diederichs S, Haber DA. Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing. Cancer Res 2006;66(12):6097-6104
31. Lujambio A, Ropero S, Ballestar E, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007;67(4):1424-1429 (Pubitemid 46383366)
32. Lodygin D, Tarasov V, Epanchintsev A, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008;7(16):2591-2600
33. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120(5):635-647 (Pubitemid 40343076)
34. Brueckner B, Stresemann C, Kuner R, et al. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 2007;67(4):1419-1423 (Pubitemid 46383365)
35. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007;104(40):15805-15810 (Pubitemid 350035380)
36. Brena RM, Morrison C, Liyanarachchi S, et al. Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer. PLoS Med 2007;4(3):e108.Published online 27 March, 2007, doi: 10.1371/journal.pmed. 0040108 (Pubitemid 46495325)
37. Tsou JA, Hagen JA, Carpenter CL, Laird-Offringa IA. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 2002;21(35):5450-5461 (Pubitemid 34983481)
38. Zochbauer-Muller S, Fong KM, Virmani AK, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer research 2001;61(1):249-255 (Pubitemid 32095725)
39. Toyooka S, Tokumo M, Shigematsu H, et al. Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res 2006;66(3):1371-1375 • This paper demonstrates epigenetic determinants of lung adenocarcinoma in individuals who never smoked. (Pubitemid 43259916)
40. Fukui T, Kondo M, Ito G, et al. Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in non-small-cell lung cancer. Oncogene 2005;24(41):6323-6327 (Pubitemid 43080055)
41. Suzuki M, Shigematsu H, Nakajima T, et al. Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer. Clin Cancer Res 2007;13(20):6087-6092 (Pubitemid 350075066)
42. Licchesi JD, Westra WH, Hooker CM, et al. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 2008;29(5):895-904 (Pubitemid 351982232)
43. Yang TM, Leu SW, Li JM, et al. WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions. J Cancer Res Clin Oncol 2008 published online 16 December 2008, doi: 10.1007/s00432-008-0527-7
44. Glaros S, Cirrincione GM, Muchardt C, et al. The reversible epigenetic silencing of BRM: implications for clinical targeted therapy. Oncogene 2007;26(49):7058-7066 (Pubitemid 350014614)
45. Glaros S, Cirrincione GM, Palanca A, et al. Targeted knockout of BRG1 potentiates lung cancer development. Cancer Res 2008;68(10):3689-3696
46. Medina PP, Carretero J, Ballestar E, et al. Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells. Hum Mol Genet 2005;14(7):973-982 (Pubitemid 40533108)
47. Reisman DN, Sciarrotta J, Wang W, et al. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res 2003;63(3):560-566 (Pubitemid 36158131)
48. Zhong S, Fields CR, Su N, et al. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 2007;26(18):2621-2634 (Pubitemid 46632003)
49. Bowman RV, Yang IA, Semmler AB, Fong KM. Epigenetics of lung cancer. Respirology 2006;11(4):355-365 (Pubitemid 43824331)
50. Bock C, Walter J, Paulsen M, Lengauer T. Inter-individual variation of DNA methylation and its implications for large-scale epigenome mapping. Nucleic Acids Res 2008;36(10):e55. Published online 15April 2008, doi: 10.1093/nar/gkn122 (Pubitemid 351859017)
51. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002;21(35):5400-5413 (Pubitemid 34983477)
52. Daskalos A, Nikolaidis G, Xinarianos G, et al. Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. Int J Cancer 2008;124(1):81-87
53. Gylling A, Ridanpaa M, Vierimaa O, et al. Large genomic rearrangements and germline epimutations in Lynch syndrome. Int J Cancer 2008;124(10):2333-2340
54. Zhou HH, Yan SY, Zhou XY, et al. MLH1 promoter germline-methylation in selected probands of Chinese hereditary non-polyposis colorectal cancer families. World J Gastroenterol 2008;14(48):7329-7334
55. Suter CM, Martin DI, Ward RL. Germline epimutation of MLH1 in individuals with multiple cancers. Nat Genet 2004;36(5):497-501 (Pubitemid 38620035)
56. Tessema M, Willink R, Do K, et al. Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25. Cancer Res 2008;68(6):1707-1714
57. Gaudet F, Hodgson JG, Eden A, et al. Induction of tumors in mice by genomic hypomethylation. Science 2003;300(5618):489-492 (Pubitemid 36444330)
58. Park JM, Lee GY, Choi JE, et al. No association between polymorphisms in the histone deacetylase genes and the risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2005;14(7):1841-1843
59. Yoon K-A, Hwangbo B, Kim I-J, et al. Novel polymorphisms in the SUV39H2 histone methyltransferase and the risk of lung cancer. Carcinogenesis, 2006;27(11):2217-2222 (Pubitemid 44644810)
60. Lee SJ, Jeon HS, Jang JS, et al. DNMT3B polymorphisms and risk of primary lung cancer. Carcinogenesis 2005;26(2):403-409 (Pubitemid 40246562)
61. Jang JS, Lee SJ, Choi JE, et al. Methyl-CpG binding domain 1 gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 2005;14(11 Pt 1):2474-2480 (Pubitemid 41752704)
62. Nuovo GJ, Plaia TW, Belinsky SA, et al. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci USA 1999;96(22):12754-12759
63. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998;95(20):11891-11896 (Pubitemid 28460510)
64. Belinsky SA, Klinge DM, Dekker JD, et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 2005;11(18):6505-6511 (Pubitemid 41338988)
65. Hsu HS, Chen TP, Hung CH, et al. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer 2007;110(9):2019-2026 (Pubitemid 350036862)
66. Hsu HS, Chen TP, Wen CK, et al. Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment. J Pathol 2007;213(4):412-419 (Pubitemid 350206513)
67. Russo AL, Thiagalingam A, Pan H, et al. Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer. Clin Cancer Res 2005;11(7):2466-2470 (Pubitemid 40569441)
68. Kim H, Kwon YM, Kim JS, et al. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J Clin Oncol 2004;22(12):2363-2370 (Pubitemid 41115393)
69. Grote HJ, Schmiemann V, Geddert H, et al. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer. Cancer 2006;108(2):129-134
70. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60(21):5954-5958 (Pubitemid 30839621)
71. Honorio S, Agathanggelou A, Schuermann M, et al. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene 2003;22(1):147-150 (Pubitemid 36152892)
72. Kersting M, Friedl C, Kraus A, et al. Differential frequencies of p16INK4a promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol 2000;18(18):3221-3229
73. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004;4(9):707-717 (Pubitemid 39215069)
74. Belinsky SA, Liechty KC, Gentry FD, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006;66(6):3338-3344
75. Fujiwara K, Fujimoto N, Tabata M, et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 2005;11(3):1219-1225 (Pubitemid 40175774)
76. Van Den Broeck A, Brambilla E, Moro-Sibilot D, et al. Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin Cancer Res 2008;14(22):7237-7245
77. Damiani LA, Yingling CM, Leng S, et al. Carcinogen-induced gene promoter hypermethylation is mediated by DNMT1 and causal for transformation of immortalized bronchial epithelial cells. Cancer Res 2008;68(21):9005-9014
78. Belinsky SA, Klinge DM, Stidley CA, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 2003;63(21):7089-7093 (Pubitemid 37413444)
79. Schrump DS, Fischette MR, Nguyen DM, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006;12(19):5777-5785 (Pubitemid 44629609)
80. Klisovic RB, Stock W, Cataland S, et al. A Phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res 2008;14(8):2444-2449 (Pubitemid 351551079)
81. Amato RJ. Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy. Clin Genitourin Cancer 2007;5(7):422-426 (Pubitemid 351219694)
82. Winquist E, Knox J, Ayoub JP, et al. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest New Drugs 2006;24(2):159-167 (Pubitemid 43723908)
83. Davis AJ, Gelmon KA, Siu LL, et al. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest New Drugs 2003;21(1):85-97 (Pubitemid 36628488)
84. Stewart DJ, Donehower RC, Eisenhauer EA, et al. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann Oncol 2003;14(5):766-774 (Pubitemid 36621778)
85. Lopez-Serra L, Ballestar E, Ropero S, et al. Unmasking of epigenetically silenced candidate tumor suppressor genes by removal of methyl-CpG-binding domain proteins. Oncogene 2008;27(25):3556-3566 (Pubitemid 351793801)
86. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37(4):391-400 (Pubitemid 40490489)
87. Barlesi F, Giaccone G, Gallegos-Ruiz MI, et al. Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol 2007;25(28):4358-4364 (Pubitemid 350013840)
88. Ramalingam SS, Parise RA, Ramanathan RK, et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 2007;13(12):3605-3610 (Pubitemid 46955122)
89. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23(17):3923-3931 (Pubitemid 46218695)
90. Reid T, Valone F, Lipera W, et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 2004;45(3):381-386 (Pubitemid 39037720)
91. Vansteenkiste J, Van Cutsem E, Dumez H, et al. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs 2008;26(5):483-488
92. Ramirez JL, Rosell R, Taron M, et al. 14-3-3σ methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. J Clin Oncol 2005;23(36):9105-9112 (Pubitemid 46260165)
93. Xing J, Stewart DJ, Gu J, et al. Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer. Br J Cancer 2008;98(10):1716-1722 (Pubitemid 351684678)
94. Lin RK, Hsu HS, Chang JW, et al. Alteration of DNA methyltransferases contributes to 5′CpG methylation and poor prognosis in lung cancer. Lung Cancer 2007;55(2):205-213 (Pubitemid 46074232)
95. Kim H, Kwon YM, Kim JS, et al. Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer 2006;107(5):1042-1049 (Pubitemid 44291153)
96. Vallbohmer D, Brabender J, Yang D, et al. DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small-cell lung cancer: association and prognostic value. Clin Lung Cancer 2006;8(1):39-44 (Pubitemid 44336242)
97. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008;358(11):1118-1128
98. Nakata S, Sugio K, Uramoto H, et al. The methylation status and protein expression of CDH1, p16INK4A, and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. Cancer 2006;106(10):2190-2199 (Pubitemid 43673241)
99. Machida EO, Brock MV, Hooker CM, et al. Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Res 2006;66(12):6210-6218
100. Suzuki M, Mohamed S, Nakajima T, et al. Aberrant methylation of CXCL12 in non-small cell lung cancer is associated with an unfavorable prognosis. Int J Oncol 2008;33(1):113-119
101. Suzuki M, Iizasa T, Nakajima T, et al. Aberrant methylation of IL-12Rβ2 gene in lung adenocarcinoma cells is associated with unfavorable prognosis. Ann Surg Oncol 2007;14(9):2636-2642 (Pubitemid 47389552)
102. Seng TJ, Currey N, Cooper WA, et al. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer 2008;99(2):375-382
103. Kim YT, Lee SH, Sung SW, Kim JH. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection? Ann Thorac Surg 2005;79(4):1180-8; discussion -8
104. Kim JS, Kim JW, Han J, et al. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res 2006;66(8):4049-4054
105. Lujambio A, Calin GA, Villanueva A, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 2008;105(36):13556-13561 • This paper provides a link between the epigenetic mechanisms of methylation and miRNAs in metastasis.
106. Belinsky SA, Grimes MJ, Casas E, et al. Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. Br J Cancer 2007;96(8):1278-1283 (Pubitemid 46625083)
107. Christensen BC, Godleski JJ, Marsit CJ, et al. Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma. Carcinogenesis 2008;29(8):1555-1559
108. Toyooka S, Pass HI, Shivapurkar N, et al. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res 2001;61(15):5727-5730 (Pubitemid 32769086)
109. Tsou JA, Shen LY, Siegmund KD, et al. Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. Lung Cancer 2005;47(2):193-204 (Pubitemid 40082162)
110. Kimura K, Toyooka S, Tsukuda K, et al. The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas. Oncol Rep 2008;20(5):1265-1268
111. Tomii K, Tsukuda K, Toyooka S, et al. Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. Int J Cancer 2007;120(3):566-573 (Pubitemid 44969028)
112. Ahuja N, Issa JP. Aging, methylation and cancer. Histol Histopathol 2000;15(3):835-842 (Pubitemid 30488566)
113. Toyooka S, Maruyama R, Toyooka KO, et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 2003;103(2):153-160 (Pubitemid 35461506)
114. Kobayashi N, Toyooka S, Yanai H, et al. Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. Lung Cancer 2008;62(1):120-125
115. Batra S, Shi Y, Kuchenbecker KM, et al. Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem Biophys Res Commun 2006;342(4):1228-1232
116. Lee AY, He B, You L, et al. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene 2004;23(39):6672-6676 (Pubitemid 39265531)
117. He B, Lee AY, Dadfarmay S, et al. Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in β-catenin-deficient human mesothelioma cells. Cancer Res 2005;65(3):743-748 (Pubitemid 40216431)
118. Kratzke RA, Wang X, Wong L, et al. Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904. J Thorac Oncol 2008;3(4):417-421
119. Creaney J, Robinson BW. Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. Hematol Oncol Clin North Am 2005;19(6):1025-1040 (Pubitemid 41736040)
120. Tsou JA, Galler JS, Wali A, et al. DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer 2007;58(2):220-230 (Pubitemid 47513257)
121. Fischer JR, Ohnmacht U, Rieger N, et al. Promoter methylation of RASSF1A, RARβ and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 2006;54(1):109-116
122. Ramalingam SS, Belani CP. Recent advances in the treatment of malignant pleural mesothelioma. J Thorac Oncol 2008;3(9):1056-1064
123. Palumbo C, Bei R, Procopio A, Modesti A. Molecular targets and targeted therapies for malignant mesothelioma. Curr Med Chem 2008;15(9):855-867 (Pubitemid 351736408)
124. Krug LM, Curley T, Schwartz L, et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006;7(4):257-261 (Pubitemid 43280028)
125. Adcock IM, Tsaprouni L, Bhavsar P, Ito K. Epigenetic regulation of airway inflammation. Current opinion in immunology 2007;19(6):694-700 • A review of epigenetics and inflammation leading to airway diseases. (Pubitemid 350236802)
126. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005;352(19):1967-1976 (Pubitemid 40638367)
127. Rahman I, Marwick J, Kirkham P. Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-κB and pro-inflammatory gene expression. Biochem Pharmacol 2004;68(6):1255-1267
128. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005;25(3):552-563 (Pubitemid 40331188)
129. Moodie FM, Marwick JA, Anderson CS, et al. Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-κB activation and proinflammatory cytokine release in alveolar epithelial cells. FASEB J 2004;18(15):1897-1899 (Pubitemid 39602276)
130. Yang SR, Chida AS, Bauter MR, et al. Cigarette smoke induces proinflammatory cytokine release by activation of NF-κB and posttranslational modifications of histone deacetylase in macrophages. Am J Physiol 2006;291(1):L46-57
131. Rahman I, Gilmour PS, Jimenez LA, MacNee W. Oxidative stress and TNF-α induce histone acetylation and NF-κB/AP-1 activation in alveolar epithelial cells: potential mechanism in gene transcription in lung inflammation. Mol Cell Biochem 2002;234-235(1-2):239-248 (Pubitemid 34777863)
132. Rajendrasozhan S, Yang SR, Edirisinghe I, et al. Deacetylases and NF-κB in redox regulation of cigarette smoke-induced lung inflammation: epigenetics in pathogenesis of COPD. Antioxid Redox Signal 2008;10(4):799-811 (Pubitemid 351225898)
133. Vincent A, Perrais M, Desseyn JL, et al. Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells. Oncogene 2007;26(45):6566-6576 (Pubitemid 47530602)
134. Thai P, Loukoianov A, Wachi S, Wu R. Regulation of airway mucin gene expression. Annu Rev Physiol 2008;70:405-429 (Pubitemid 351738186)
135. Ito K, Yamamura S, Essilfie-Quaye S, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression. J Exp Med 2006;203(1):7-13 (Pubitemid 43139638)
136. Adcock IM, Ito K, Barnes PJ. Histone deacetylation: an important mechanism in inflammatory lung diseases. COPD 2005;2(4):445-455 (Pubitemid 43879443)
137. Bhavsar P, Ahmad T, Adcock IM. The role of histone deacetylases in asthma and allergic diseases. J Allergy Clin Immunol 2008;121(3):580-584
138. Hollingsworth JW, Maruoka S, Boon K, et al. In utero supplementation with methyl donors enhances allergic airway disease in mice. J Clin Invest 2008;118(10):3462-3469
139. Yang Y, Haitchi HM, Cakebread J, et al. Epigenetic mechanisms silence a disintegrin and metalloprotease 33 expression in bronchial epithelial cells. J Allergy Clin Immunol 2008;121(6):1393-1399, 9 e1-14
140. Kwon NH, Kim JS, Lee JY, et al. DNA methylation and the expression of IL-4 and IFN-γ promoter genes in patients with bronchial asthma. J Clin Immunol 2008;28(2):139-146
141. Sanders YY, Pardo A, Selman M, et al. Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am J Respir Cell Mol Biol 2008;39(5):610-618
142. Umemura S, Fujimoto N, Hiraki A, et al. Aberrant promoter hypermethylation in serum DNA from patients with silicosis. Carcinogenesis 2008;29(9):1845-1849
143. Yauk C, Polyzos A, Rowan-Carroll A, et al. Germ-line mutations, DNA damage, and global hypermethylation in mice exposed to particulate air pollution
144. Liu J, Ballaney M, Al-alem U, et al. Combined inhaled diesel exhaust particles and allergen exposure alter methylation of T helper genes and IgE production in vivo. Toxicol Sci 2008;102(1):76-81 (Pubitemid 351265126)
145. Miller RL, Ho SM. Environmental epigenetics and asthma: current concepts and call for studies. Am J Respir Crit Care Med 2008;177(6):567-573
146. Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu Rev Pharmacol Toxicol 2009;49:243-263 • This paper describes the future potential for therapeutics.